FEELM
21.11.2022 13:48:38 CET | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won Best Innovation in the Vaping Industry and Sustainable Vaping Award at the UKVIA Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005487/en/
FEELM won the UKVIA Best Innovation Award. (Photo: Business Wire)
UKVIA is one of the world's most influential trade associations for the vaping sector. It is also one of the most accredited industrial association in Europe. This is the first time they held an award competition ever since their establishment in 2016. The competition is consisted of three sessions: online application, audiences review, and experts scoring. FEELM Max won the victory after rounds of assessments of more than 300 audiences and 10 experts.
The Best Innovation in the Vaping Industry
The Best Innovation in the Vaping Industry recognized the significant contribution FEELM has made to vaping innovation, particularly its world's first ceramic coil disposable pod solution FEELM Max.
FEELM Max has made a number of breakthrough innovations, including more puffs with the same e-liquid volume versus other coil technologies. Despite heating the same e-liquid volume as other conventional devices, puff numbers increase by more than 25%. FEELM Max achieves a flavour consistency of over 95% as well as a smoother vapour – and there is no dry burning – thanks to Constant Output Control and our Patented Flavour-Lock Technologies. Not only is FEELM Max enhancing the vaping experience, but it is also outperforming other disposables on harm reduction by almost 50%.
To stand still on the path of innovation, FEELM has established China’s first PMTA-standard testing lab besides the now-existing 14 labs globally, to empower our clients facing with the stringent regulations on the industry. This is to prove our determination to drive innovation with technology, and keep providing products with enhanced quality to consumers.
The Sustainable Vaping Award
The Sustainable Vaping Award was given in recognition of FEELM excelling in three key areas: creating sustainable advanced technologies and products; using responsible marketing; and embracing a greener future.
FEELM is credited with building the world's first environmentally friendly disposable electronic atomization device in 2019. In 2022, the world's first ceramic coil disposable pod "FEELM Max" was created and the "FEELM GREEN" series was launched based on it. This series is FEELM Max's main environmental protection solutions, its latest "product is packaging" series has been presented at the major European electronic atomization exhibition, aroused the industry's high attention. In addition, FEELM also created an environmentally friendly zero nicotine e-atomization device this year.
It was also acknowledged that its brand website and social media platforms go to great lengths to restrict those who are under the legal age of vaping to prevent them from accessing any information about electronic atomization products; and that FEELM conducts regular satisfaction surveys on behalf of clients so data can be used to improve customer experience.
FEELM has announced its launching of the Carbon Disclosure Project (CDP), committing to achieve carbon neutrality by 2050, and its automated factory has adopted an energy management system with the purpose of decreasing carbon emissions whilst increasing energy consumption efficiency
The Award is also recognition of FEELM’s cut in carbon emissions of over 500 tons in the last six months, and its aim to lower greenhouse gas emissions and achieve Scope 1 and Scope 2 carbon neutrality by 2050. The company intends to achieve this by improving energy efficiency and increasing the use of renewable energy sources to 30% of total consumption by 2030 and has accordingly introduced a professional carbon neutral energy screening team and internal resources to monitor carbon consumption improvement. It has also partnered with a third-party cleaning company to collect non-hazardous waste for recycling, which in 2020 helped clients reduce single-use plastics by 100 tons – equivalent to 4 million plastic bottles, while in 2021 it reduced its water consumption by 9.4% year-on-year.
Echo liu, FEELM Europe Division Director said:
“We are delighted to have won both awards and honoured by the recognition the UKVIA have given us.”
“A number of leading vaping brands are driven by FEELM Technology, and our vaping devices loaded with FEELM atomizer are now being exported to over 50 countries and regions.”
“FEELM can only realize its corporate vision – “atomization makes life better” – by being sustainable and creating value for society. Every day we move a step closer to this goal by creating sustainable advanced technologies and products, using responsible marketing, and embracing a greener future.”
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom